Home » Stocks » Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc. (SBPH)

Stock Price: $1.44 USD -0.02 (-1.37%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 24.84M
Revenue (ttm) n/a
Net Income (ttm) -29.07M
Shares Out 17.25M
EPS (ttm) -1.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $1.44
Previous Close $1.46
Change ($) -0.02
Change (%) -1.37%
Day's Open 1.46
Day's Range 1.43 - 1.49
Day's Volume 49,762
52-Week Range 0.80 - 4.80

More Stats

Market Cap 24.84M
Enterprise Value 4.13M
Earnings Date (est) Nov 3, 2020
Ex-Dividend Date n/a
Shares Outstanding 17.25M
Float 14.88M
EPS (basic) -1.74
EPS (diluted) -1.75
FCF / Share -1.54
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 54,565
Short Ratio 0.08
Short % of Float 0.24%
Beta 1.26
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 0.91
Revenue n/a
Operating Income -28.43M
Net Income -29.07M
Free Cash Flow -26.32M
Net Cash 20.70M
Net Cash / Share 1.20
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -40.31%
ROE -81.68%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 0
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

$1.75*
(21.53% upside)
Low
1.50
Current: $1.44
High
2.00
Target: 1.75
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue---0.350.950.74
Revenue Growth----62.79%28.18%-
Gross Profit---0.350.950.74
Operating Income-33.02-28.47-21.25-19.40-11.60-7.81
Net Income-24.10-22.85-27.68-17.37-11.56-9.71
Shares Outstanding16.4514.3711.157.265.683.12
Earnings Per Share-1.46-1.88-2.48-2.39-2.03-3.11
Operating Cash Flow-29.06-25.24-17.68-15.82-8.21-7.38
Capital Expenditures-0.27-1.97-0.32-0.21-0.39-0.06
Free Cash Flow-29.33-27.22-18.01-16.03-8.60-7.43
Cash & Equivalents54.6947.8751.0424.739.681.57
Total Debt22.29-----
Net Cash / Debt32.4047.8751.0424.739.681.57
Assets63.2068.8152.3426.8814.5813.81
Liabilities27.6712.9517.599.863.551.61
Book Value35.5355.8634.7517.0211.0312.20
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Spring Bank Pharmaceuticals, Inc.
Country United States
Employees 30
CEO Martin J. Driscoll

Stock Information

Ticker Symbol SBPH
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SBPH
IPO Date May 6, 2016

Description

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.